Levi Garraway, MD, PhD
In topline results from the phase III JUNIPER trial, abemaciclib (Verzenio) failed to meet its primary endpoint of improving overall survival (OS) versus erlotinib (Tarceva) in patients with KRAS
-mutated, advanced non–small cell lung cancer (NSCLC) who progressed after platinum-based chemotherapy.
However, the drug showed activity in an analysis of the secondary endpoints of progression-free survival (PFS) and overall response rate (ORR), according Lilly Oncology, the manufacturer of the CDK4/6 inhibitor.
... to read the full story